卡维地洛在二级预防中较普萘洛尔获得更高的血流动力学应答率和更低的再出血率
这项回顾性分析纳入87例接受配对HVPG测量指导二级预防的肝硬化患者(卡维地洛45例、普萘洛尔42例),所有患者均接受套扎治疗。卡维地洛组HVPG相对下降幅度更大(中位-20% vs -11%,P=0.027),慢性HVPG应答率更高(53.3% vs 28.6%,P=0.034),再出血和肝相关死亡累积发生率更低。
要点
- 卡维地洛组HVPG中位相对下降-20%,普萘洛尔组-11%(P=0.027)。
- 卡维地洛组慢性HVPG应答率53.3%,普萘洛尔组28.6%(P=0.034)。
- 卡维地洛组再出血(P=0.027)和肝相关死亡(P=0.036)累积发生率更低。
核心结论
- 卡维地洛在静脉曲张出血二级预防中较普萘洛尔更显著降低HVPG,并与更低的再出血、肝相关死亡及非出血性失代偿发生率相关。
研究设计与样本
- 回顾性分析纳入接受配对HVPG测量指导二级预防的肝硬化患者87例,卡维地洛组45例、普萘洛尔组42例,所有患者均接受套扎治疗。
主要发现
- 基线HVPG中位值为21 mm Hg(四分位距18-24 mm Hg),Child-Turcotte-Pugh A/B/C级分别占39.1%/48.3%/12.6%。
- 卡维地洛组HVPG中位相对下降-20%(四分位距-29%至-10%),普萘洛尔组-11%(四分位距-22%至-5%),P=0.027。
- 卡维地洛组慢性HVPG应答率53.3%,普萘洛尔组28.6%,P=0.034。
- 卡维地洛组再出血累积发生率(Gray检验P=0.027)和肝相关死亡累积发生率(P=0.036)显著低于普萘洛尔组。
- 卡维地洛组腹水发生/加重更少见(P=0.012),两组急性肾损伤发生率无差异(P=0.255)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. METHODS: Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis. All patients also underwent band ligation. Changes in HVPG and systemic hemodynamics were compared between the 2 groups. Long-term follow-up data on rebleeding, acute kidney injury, nonbleeding decompensation, and liver-related death were analyzed applying competing risk regression. RESULTS: Eighty-seven patients (carvedilol/propranolol, n = 45/42) were included in our study. The median baseline HVPG was 21 mm Hg (interquartile range, 18-24 mm Hg), and 39.1%/48.3%/12.6% had Child-Turcotte-Pugh A/B/C cirrhosis, respectively. Upon nonselective β-blocker initiation, HVPG decreased more strongly in carvedilol users (median relative decrease, -20% [interquartile range: -29% to -10%] vs -11% [-22% to -5%] for propranolol; P = .027), who also achieved chronic HVPG response more often (53.3% vs 28.6%; P = .034). Cumulative incidences for rebleeding (Gray test, P = .027) and liver-related death (P = .036) were significantly lower in patients taking carvedilol compared with propranolol. Notably, ascites development/worsening also was observed less commonly in carvedilol patients (P = .012). Meanwhile, acute kidney injury rates did not differ between the 2 groups (P = .255). Stratifying patients by HVPG response status yielded similar results. The prognostic value of carvedilol intake was confirmed in competing risk regression models. CONCLUSIONS: Carvedilol induces more marked reductions in HVPG than propranolol in secondary prophylaxis of variceal bleeding, and thus is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation.
引用
- Jachs M, Hartl L, Simbrunner B, et al. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. Clin Gastroenterol Hepatol. 2022. PMID: 35842118. doi:10.1016/j.cgh.2022.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。